Overview
This patient-centric symposium will explore navigating the patient journey with asparaginase therapies as part of the treatment strategy for acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). The lively and engaging format will feature a series of video-based clinical vignettes, each modeling best practices in patient-clinician communication, contextualized within a review of the essential role of currently available asparaginase therapies in the optimal management of ALL/LBL. Faculty commentary and expert guidance will focus on how to select therapy, assess treatment efficacy, and recognize and manage the wide range of potential toxicities associated with asparaginase treatment. The expert faculty panel will include an adult hematologist/oncologist, a pediatric hematologist/oncologist, a hematologic oncology nurse specialist, and a patient advocate.
Speakers
Ibrahim T. Aldoss, MD
MODERATOR
Associate Professor
Division of Leukemia
Department of Hematopoietic Cell Transplantation
City of Hope Duarte Cancer Center
Duarte, California
Luke Maese, DO
PANELIST
Associate Professor of Pediatrics
Department of Hematology/Oncology
University of Utah Huntsman Cancer Institute
Children’s Hospital
Salt Lake City, Utah
Sandra Kurtin, PhD, ANP-BC, AOCN, FAPO
PANELIST
Clinical Assistant Professor of Medicine
Adjunct Clinical Professor of Nursing
Director
Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Tucson, Arizona
Cate O'Reilly, MSW
PATIENT ADVOCATE
Patient and Caregiver Advocate
Cancer Support Community
Washington, DC
Agenda
3:30 pm
Welcome to the ALL/LBL Clinic
Ibrahim T. Aldoss, MD
3:35 pm
Setting the Stage: Voicing Patient and Family Perspectives of Living With ALL/LBL
Cate O'Reilly, MSW
3:45 pm
Scene 1: Starting a Treatment Regimen That Includes Asparaginase Therapy
Luke Maese, DO
4:05 pm
Scene 2: Understanding Potential Toxicities of Asparaginase Therapy
Sandra Kurtin, PhD, ANP-BC, AOCN, FAPO
4:25 pm
Scene 3: Discussing Next Steps After an Adverse Reaction to Asparaginase Therapy
Ibrahim T. Aldoss, MD
4:45 pm
The ALL/LBL Clinic: Looking to the Future
All Faculty
4:50 pm
Expert Q&A
All Faculty
333 West Harbor Drive,
Marriott Grand Ballroom 5-6,
San Diego, California,
92101
United States
United States
Program Information
Accreditation Statement
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold][break]
Medscape, LLC designates this live activity for a maximum of 1.50 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
[break][break]
[bold]For Nurses[/bold][break]
Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.
[break][break]
[bold]For Pharmacists[/bold][break]
Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-258-L01-P).
Learning Objectives
Upon completion of this activity, participants will:[break]
Have increased knowledge regarding the
[list][item]Therapeutic monitoring recommendations for patients with ALL/LBL receiving asparaginase therapies
[item]Toxicities associated with asparaginase therapies
[/list]Have greater competence related to:
[list][item]Selecting the most appropriate treatment approach for the individual patient with ALL/LBL
[item]Managing subsequent treatment in patients with ALL/LBL who experience asparaginase-related toxicities
[/list]Demonstrate greater confidence in their ability to
[list][item]Communicate effectively with patients and their families regarding the management of ALL/LBL with asparaginase therapies
Goal Statement
The goal of this activity is to provide clinicians with practical strategies to improve their ability to integrate and manage asparaginase therapies as part of patient-centered care of ALL/LBL to maximize outcomes for the individual patient.
Target Audience
This activity is intended for hematologist/oncologists (including pediatric hematologist/oncologists), nurses, nurse practitioners, pharmacists, and other members of the ALL/LBL care team.
A Friday Satellite Symposium on Hematology, preceding the 66th ASH Annual Meeting and Exposition.
Supported by an independent educational grant from Jazz Pharmaceuticals, Inc.